Navigation Links
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Date:4/1/2011

BERLIN and RIDGEFIELD, Conn., April 1, 2011 /PRNewswire/ -- New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 (GT1) hepatitis C virus (HCV), the most challenging genotype of HCV to treat.  Results from SILEN-C1 show a sustained viral response (SVR) in 71 to 83 percent of treatment-naive patients who received BI 201335 once-daily plus the current standard-of-care (SOC) [pegylated interferon (PegIFN) and ribavirin (RBV)].

Results from SILEN-C2 show an SVR in 28 to 41 percent of treatment-experienced patients who received BI 201335 once-daily plus PegIFN and RBV.

"SILEN-C1 and 2 have shown positive Phase 2 results in a broad range of HCV patients," said Peter Piliero, M.D., executive director, Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "The current standard-of-care in HCV is not effective for enough patients. Protease inhibitors such as BI 201335 represent potential new options to improve outcomes and the possibility to shorten the duration of treatment for HCV disease."

"Boehringer Ingelheim is continuing its long heritage in virology and commitment to develop new medicines for HCV," continued Piliero. "BI 201335 is part of BI's growing HCV portfolio, which is being investigated with the goal of improving treatment and cure rates for HCV patients.  We are excited that we will commence our Phase 3 trial program with BI 201335 in the near future, based on the results of these Phase 2 studies."

(Oral abstract #60) SILEN-C1: Sustained Virologic Response (SVR) and Safety of BI 201335 Combined with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Genotype-1 HCV InfectionIn this double-blind, randomized, placebo-controlled trial, 429 treatment-na
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Research and Markets has announced the ... Report, 2014-2016" report to their offering. ... percutaneous coronary intervention (PCI), serves not only as a ... for pre-/post-stent dilatations. Therefore, the development of PTCA balloon ... As national economy develops and people,s living standard ...
(Date:9/18/2014)... 2014   Fruit Street Health (Fruit Street), ... round of funding. The round, which ... series of individual investors, the majority of whom are ... initial round are; Houston Cardiology Consultants Partner Asif ... Childs, Rapha Family Medicine Practice Owner Frances Ilozue ...
(Date:9/18/2014)... 2014  Decision Resources Group finds that Regeneron,s Eylea, ... agent for wet AMD, is equally likely to be ... Lucentis, which is the standard of care for wet ... directors do not identify a clear clinical or economic ... Lucentis to be listed on tier 1 or 2 ...
Breaking Medicine Technology:China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
(Date:9/19/2014)... caused by the bacterium Mycobacterium avium ... legal obligation to report the disease. Paratuberculosis mainly ... among affected animals. The disease can cause considerable ... less milk, exhibit fertility problems and are more ... , To date there has been no ...
(Date:9/19/2014)... September 19, 2014 Lifeinsure.biz has ... insurance riders that can be purchased without medical examinations. ... up and make a life insurance policy more advantageous. ... find more about extra options available for a no ... without medical examinations required is simple to purchase, however ...
(Date:9/19/2014)... 19, 2014 2014 Market Research ... professional and in-depth research report on Kinesio tape ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... environment & economic situation analysis. The report on, ...
(Date:9/19/2014)... York (PRWEB) September 19, 2014 Business ... Game Building Platform . Earlier this month Appy Pie was ... Tools for the Aspiring App Developer' by Yahoo . , ... allows people to develop beautiful applications within minutes and it ... With advanced features and support for latest mobile operating systems, ...
(Date:9/19/2014)... The dentist at Encino Esthetic Dental Group ... the month of September, new patients will be able to ... $69. A complimentary home teeth whitening kit will be included. ... checked and meet the team at Encino Esthetic Dental Group. ... oral health. According to the American Dental Association, biannual checkups ...
Breaking Medicine News(10 mins):Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2Health News:Kinesio Tape Industry Analysis for North America, Europe, Asia & ROW Key Company Market Status Now at LifeScienceIndustryResearch.com 2Health News:Kinesio Tape Industry Analysis for North America, Europe, Asia & ROW Key Company Market Status Now at LifeScienceIndustryResearch.com 3Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Encino Esthetic Dental Group is Now Offering a Special Promotion for New Patients 2
... Cancer ... President, Nutrition, National Cattlemen,s ... Beef Association, DENVER, Oct. 31 "The WCRF/AICR recommendations about,red ... research about the benefits of red meat in a healthy,diet that far outweigh anything ...
... will Accelerate Expansion of Industry Leading Health and Human ... Services On-Demand Software Solutions, ... industry-leading provider of software solutions for the,health and human services ... and debt financing totaling $28 million. The round was led,by ...
... a 70-cm Open-Bore, Design to Bring High-Resolution MR Imaging to ... ... Before, MALVERN, Pa., Oct. 31 Combining 3 Tesla strength and,sensitivity ... the MAGNETOM(R),Verio, a 3 Tesla (T) MRI system with a 70 cm ...
... encourage health behavior change increasing, LYNDHURST, N.J., ... the 3rd quarter of 2007, with agreements to ... at initial rollout,six million when programs are fully ... Health and Productivity division, which combines the use,of ...
... even Alzheimer,s, experts say , , WEDNESDAY, Oct. 31 (HealthDay News) ... brain,s own stem cells may have the ability to restore ... by protecting existing cells and promoting neuronal connections. , In ... were able to bring the rodents, memory back to healthy ...
... for hepatocytes; viral antigen also has been detected in ... hepatic failure but rarely reported in acute viral hepatitis. ... three year period were involved. Acute abdominal pain was ... 17 had stretching of glissons capsule as a cause. ...
Cached Medicine News:Health News:NCBA Statement on 2007 WCRF/AICR Second Expert Report on Food, Nutrition and Physical Activity and the Prevention of Cancer: 2Health News:Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank 2Health News:Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank 3Health News:Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank 4Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 2Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 3Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 4Health News:IncentOne Adds 14 New Clients Year to Date to Health and Productivity Division 2Health News:IncentOne Adds 14 New Clients Year to Date to Health and Productivity Division 3Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3Health News:Is it pancreatitis in acute abdominal pain in acute viral hepatitis? 2
Nitinol Flat Wire Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: